Oxford Drug Design awarded £1m PACE funding to progress uUTI treatment
As part of company’s tRNA synthetase development in oncology and infections Oxford Drug Design has been awarded £1m in funding to progress […]
Oxford Drug Design achieves further in vivo validation of novel approach against multiple tumours
Oxford Drug Design, the Oxford-based AI drug discovery company, has announced today additional in vivo validation for its first-in-class approach against cancer […]
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy. The CRUK (Cancer Research UK) Scotland Institute […]